The initial symptoms of GVHD typically appear on the skin, often because GVHD first damages and causes inflammation in skin cells, says Azra Borogovac, MD, a hematologist at City of Hope in Irvine ...

Medically reviewed by Marla Anderson, MD Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which ...

and skin rashes. Chronic GVHD tends to occur more than 100 days after a transplant, and symptoms are also usually mild. But some people are at risk of more serious complications, including lichen ...

GvHD causes life-threatening immune system reactions in the skin, gastrointestinal (GI ... Many differences exist between human and mouse immune systems and their MSCs. Instead, he says, more ...

the potential for GvHD is greatly reduced. The dual effect has been demonstrated in mouse models of allogeneic HSCT, and mocravimod has been found to be safe and well-tolerated in human safety ...

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a ...

The graft is grown from mouse stem cells engineered by CRISPR to produce the GLP ... this would be “like another way of taking a drug orally—in this case it’s on your skin,” he says. The stem cells ...

The team explored the potential of regenerative mesenchymal stem cells in reducing ocular inflammation in GVHD-infected mice.

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit ... scleroderma that causes skin hardening and organ damage.

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.